This book does nothing less than lay out the state of development of tomorrow’s cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities. The sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to derive more efficient drugs targeting cancer pathway components? Promising cell surface molecules, potential targets of monoclonal antibodies, and intracellular molecules with enzymatic activity, potential targets for low-molecular-weight synthetic inhibitors, have been identified.Our ability to predict the consequences of inhibition of such components, however, is still limited. For this reason, the development of targeted drugs remains a complex process, comprising rational and empirical elements. Thus this book is covering an area of vital importance in contemporary medical research.
DETTAGLI PRODOTTO torna su
Titolo: Targeted Interference with Signal Transduction Events
Editore: Springer Verlag
Collana: Recent Results in Cancer Research
Finitura: Copertina rigida